Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 due to DGAT2 Mutation

Autosomal Dominant Charcot-Marie-Tooth Disease Type 2 due to DGAT2 Mutation is a very rare, inherited nerve disease. It affects the axons—the long “wires” of the peripheral nerves that carry signals to and from your limbs. Because the problem is mainly in the axon (not the myelin insulation), doctors classify it as Charcot-Marie-Tooth type 2 (CMT2). In a few reported families, a single misprint (pathogenic variant) in the DGAT2 gene—an enzyme that makes triglycerides (a kind of fat)—has been linked to a length-dependent axonal neuropathy. Children often first show symptoms with slowly worsening weakness and thinning of muscles in the feet and legs, later the hands, along with reduced sensation, balance trouble, and decreased reflexes. It runs in autosomal dominant fashion—one altered copy of the gene is enough to cause the disorder. PubMed+2Orpha+2

CMT2-DGAT2 is a rare inherited nerve disease where long nerves in the arms and legs slowly degenerate (an “axonal neuropathy”), causing weakness and wasting in the feet and lower legs first, later hands, with sensory loss, imbalance (ataxia), reduced reflexes, and sometimes tremor. It follows an autosomal dominant pattern—one changed copy of the gene can cause disease—and has been linked to a specific change in the DGAT2 gene (for example, p.Tyr223His). DGAT2 encodes diacylglycerol O-acyltransferase 2, a key enzyme in making triglycerides; the mutation seems to disturb lipid handling in nerve cells, which contributes to nerve fiber degeneration over years. Reported families show childhood or early-adult onset and slow progression. PubMed+2Orpha+2

Why DGAT2 matters: DGAT2 helps build triglycerides in cells. Research suggests that abnormal DGAT2 can disturb lipid handling in nerve cells, stressing long axons and making them vulnerable to degeneration over time. Broader work in neuropathy also connects disturbed lipid metabolism to nerve damage. PMC+3PubMed+3Cell+3

---

Other names

• Autosomal dominant CMT2 due to DGAT2 mutation

• CMT2 (DGAT2-related)

• Hereditary motor and sensory neuropathy type 2 due to DGAT2

• Orphanet: ORPHA:487814; MONDO: MONDO:0044625. Orpha+1

---

Types

Doctors group CMT by where the main damage occurs and by inheritance:

• CMT1 – demyelinating (myelin problem), usually autosomal dominant.

• CMT2 – axonal (axon problem), can be dominant or recessive. DGAT2-related disease fits here (CMT2).

• Intermediate, CMT4 (recessive demyelinating), and X-linked forms also exist, but are different categories. Charcot-Marie-Tooth Disease

---

Causes

Because this is a genetic condition, the primary “cause” is the pathogenic DGAT2 variant. The items below explain mechanisms and common contributors that trigger or aggravate the axonal injury over a lifetime.

1. Pathogenic DGAT2 variant (autosomal dominant): A single harmful change in DGAT2 leads to CMT2 in reported families. PubMed+1

2. Impaired triglyceride synthesis at the ER: Faulty DGAT2 disrupts the final step of triglyceride formation, upsetting membrane and energy balance in neurons. PubMed

3. Axonal lipid dysregulation: Long axons depend on precise lipid supply; imbalance predisposes to axonal degeneration. Cell

4. Mitochondrial stress in axons: Lipid imbalance can raise oxidative stress and energy failure in long peripheral axons. Cell

5. Endoplasmic reticulum (ER) stress: Disturbed lipid handling can stress the ER, impairing protein/lipid homeostasis. Cell

6. Length-dependent vulnerability: The farthest nerve endings (feet) are most vulnerable, so symptoms start distally. Europe PMC

7. Secondary myofiber deconditioning: Weakness reduces activity; inactivity further weakens distal muscles. (General CMT physiology.) NCBI

8. Superimposed entrapment neuropathies (e.g., carpal tunnel): Narrow tunnels can further injure already fragile axons. (General CMT complication.) NCBI

9. Poor ankle/foot mechanics (pes cavus, hammertoes): Abnormal foot shape increases falls and microtrauma to nerves. (Common in CMT.) NCBI

10. Metabolic stressors (prediabetes, dyslipidemia): Systemic lipid/glucose issues are linked with nerve injury and may worsen axon stress. PMC

11. Nutritional deficiency (e.g., B12): Does not cause DGAT2-CMT, but can add neuropathy burden if present. (General neuropathy principle.) NCBI

12. Alcohol-related nerve toxicity: Can layer additional axonal damage. (General neuropathy principle.) NCBI

13. Chemotherapy neurotoxicity (e.g., vincristine): Certain drugs are more harmful in hereditary neuropathies. (General CMT caution.) NCBI

14. Thyroid dysfunction: Can worsen neuropathic symptoms if untreated. (General neuropathy.) NCBI

15. Infections causing deconditioning: Illness decreases activity, worsening weakness and balance. (General CMT care.) NCBI

16. Obesity/limited mobility: Extra load and less movement amplify gait problems and falls. (General CMT.) NCBI

17. Ankle instability and recurrent sprains: Weak peroneal muscles → more sprains → more disability. (General CMT feature.) NCBI

18. Poor footwear: Inadequate support increases falls, pressure points, and pain. (General CMT management.) Mayo Clinic

19. Vitamin E deficiency (rare): Can mimic/worsen neuropathy; treatable if present. (General neuropathy.) NCBI

20. Aging of long axons: Natural axon aging on top of genetic vulnerability increases impairment over decades. (CMT natural history.) NCBI

---

Symptoms

1. Foot and ankle weakness: You may struggle to lift the front of the foot (foot drop), trip, or catch toes on the ground. Genetic & Rare Diseases Center

2. Calf and foot muscle wasting: Lower legs can look thinner (“inverted champagne bottle”). NCBI

3. High-arched feet (pes cavus) and hammertoes: The foot shape changes over time and makes shoes uncomfortable. NCBI

4. Hand weakness (later): Buttoning clothes, writing, or opening jars becomes harder. Genetic & Rare Diseases Center

5. Numbness/tingling: Reduced feeling in toes and feet at first, then fingers. Genetic & Rare Diseases Center

6. Poor balance/ataxia: Wide-based or unsteady gait; frequent minor falls. Genetic & Rare Diseases Center

7. Decreased reflexes: Ankle jerks are often reduced or absent. Genetic & Rare Diseases Center

8. Tremor (hands): A fine shake can appear in the hands. Genetic & Rare Diseases Center

9. Leg cramps and fatigue: Especially after walking or standing. NCBI

10. Neuropathic pain (variable): Burning, pins-and-needles, or aches in feet/hands. NCBI

11. Frequent ankle sprains: Weak stabilizers make the ankle roll easily. NCBI

12. Cold feet/temperature sensitivity: Reduced small-fiber function can alter thermal sensation. NCBI

13. Slow, progressive course: Symptoms usually build over years rather than days. Europe PMC

14. Childhood or teen onset: Many families report early onset, with slow progression. Genetic & Rare Diseases Center

15. Family history in a dominant pattern: Multiple generations affected. Orpha

---

Diagnostic tests

A) Physical examination (bedside checks)

1. Neurologic exam of strength and tone: The clinician checks ankle/toe and later hand muscles, looking for distal weakness and wasting. This helps confirm a distal-predominant pattern typical of CMT2. NCBI

2. Reflex testing: Ankle reflexes are often reduced or absent; knees may be reduced too. This supports peripheral neuropathy. Genetic & Rare Diseases Center

3. Sensory testing: Light touch, pinprick, vibration, and position sense are checked; distal loss is common. Patterns help distinguish axonal vs demyelinating features. NCBI

4. Gait and balance assessment: Walking pattern (wide-based, steppage gait) and Romberg testing identify ataxia and proprioceptive loss. Genetic & Rare Diseases Center

5. Foot structure evaluation: Looking for pes cavus, hammertoes, calluses helps document orthopedic complications needing bracing or orthotics. NCBI

B) Manual and functional tests

6. Manual muscle testing (MMT) or handheld dynamometry: Measures specific distal muscle strength over time to track progression and guide rehab plans. NCBI

7. Timed walk/6-minute walk test: Quantifies endurance and mobility, showing how neuropathy affects daily function. NCBI

8. 9-Hole Peg Test or grip dynamometry: Checks fine motor coordination and hand strength when hands become involved. NCBI

9. Balance tests (e.g., single-leg stance): Simple clinic measures detect instability and fall risk; results inform PT. NCBI

10. Functional gait assessment or foot/ankle proprioception tasks: Identify need for ankle-foot orthoses (AFOs) or balance training. Mayo Clinic

C) Laboratory and pathological tests

11. Targeted or panel-based genetic testing: Confirms the diagnosis by identifying a DGAT2 pathogenic variant; panels cover dozens of CMT genes and can be ordered after clinical suspicion and electrodiagnostic confirmation. PubMed+1

12. Nerve biopsy (rarely needed today): Historically used to distinguish axonal vs demyelinating neuropathy; now reserved for atypical cases. NCBI

13. Metabolic labs (B12, thyroid, glucose, lipids): Not to diagnose DGAT2-CMT, but to identify and treat additional neuropathy contributors (e.g., diabetes, dyslipidemia) that can worsen function. PMC

14. Creatine kinase (CK): Often normal or mildly elevated; helps rule out primary muscle disease when weakness is prominent. NCBI

15. Autoimmune/other neuropathy screens (as indicated): Used when the presentation is atypical or rapidly progressive to exclude other disorders. Blue Cross Blue Shield of Massachusetts

D) Electrodiagnostic tests (key for CMT2)

16. Nerve conduction studies (NCS): In CMT2, conduction velocities are not severely slowed; amplitudes can be reduced (axonal loss). This helps classify the neuropathy as axonal vs demyelinating and guides genetic testing. NCBI+2NCBI+2

17. Electromyography (EMG): Shows chronic denervation and reinnervation patterns in distal muscles, supporting an axonal process and quantifying severity. NCBI

18. F-waves and late responses: Helpful to assess proximal segments and overall axonal integrity when standard NCS are borderline. Experts in CMT

E) Imaging and structure-function tests

19. Foot/ankle X-rays: Assess cavus deformity, hammertoes, and joint alignment to plan orthotics or surgery if needed. Mayo Clinic

20. Muscle MRI or ultrasound of calves/feet: Noninvasive view of distal muscle atrophy and fatty replacement; helpful for staging and differential diagnosis in select centers. NCBI

Non-pharmacological treatments (therapies & other supports)

Note: For readability, I’m giving concise versions here; if you’d like full ~150-word mini-essays (description, purpose, mechanism) for each of the 20 items, I can generate them next.

1. Individualized physiotherapy program — graded resistance for dorsiflexors/plantarflexors and intrinsic hand muscles; improves strength, endurance, and gait efficiency; reduces contracture risk. MDPI+1

2. Balance and proprioception training — wobble boards, tandem gait; reduces falls by training sensory-motor integration when distal sensation is reduced. MDPI

3. Stretching & range-of-motion — daily calf/hamstring and hand stretches prevent equinus and clawing contractures. nhs.uk

4. Aerobic conditioning — low-impact cycling, swimming maintain cardiorespiratory fitness without overloading weak ankles. Physiopedia

5. Task-specific gait training — foot clearance drills, obstacle negotiation; improves safety and community ambulation. Cureus

6. Ankle-foot orthoses (AFOs) — correct foot drop, improve toe clearance and stability; choice of in-shoe orthoses vs AFO per algorithm. The Foundation for Peripheral Neuropathy

7. Custom footwear & insoles — redistribute pressure, accommodate cavus/claw toes, reduce pain and ulcer risk. PMC

8. Occupational therapy (hand & ADL aids) — splints, adaptive utensils, energy conservation to preserve independence. cmtausa.org

9. Home fall-prevention modifications — lighting, remove loose rugs, railings; reduces injury burden in sensory ataxia. NCBI

10. Pain psychology/CBT & pacing — reframing, pacing, sleep hygiene to lessen pain-related disability. NCBI

11. Vocational rehab & ergonomics — job task adaptation, braces or typing aids to sustain employment. cmtausa.org

12. Community-based exercise classes — supervised programs maintain adherence and social support. MDPI

13. Neuromuscular electrical stimulation (selected cases) — adjunct for severely weak dorsiflexors when tolerated. MDPI

14. Weight management & metabolic health — excess weight stresses weak ankles; healthier lipids may favor nerve health. Frontiers

15. Foot care education — daily checks, nail care, blister prevention; crucial with sensory loss. nhs.uk

16. Tremor management strategies — weighted utensils, bracing, task modification. NCBI

17. Assistive devices — canes/trekking poles improve stability outdoors. NCBI

18. Hydrotherapy — buoyancy allows safe gait practice without ankle overload. MDPI

19. Patient education & peer support — understanding natural history improves coping and safe activity. U.S. Food and Drug Administration

20. Genetic counseling — inheritance risk discussion, family testing options. Orpha

---

Drug treatments

There are no FDA-approved drugs that modify CMT2-DGAT2. Medications below are FDA-labeled for neuropathic pain syndromes (e.g., diabetic peripheral neuropathy, postherpetic neuralgia) and are commonly used symptomatically in CMT after clinician judgment. Always individualize dosing/safety. U.S. Food and Drug Administration

1. Duloxetine (Cymbalta) — Class: SNRI. Indication: diabetic peripheral neuropathic pain (DPN). Typical dose/time: 60 mg once daily. Purpose: reduce neuropathic pain intensity and improve function. Mechanism: boosts spinal descending monoaminergic inhibition of pain signaling. Key adverse effects: nausea, somnolence, dry mouth; warnings for hepatotoxicity/serotonin syndrome. Label source. FDA Access Data+1

2. Pregabalin (Lyrica / Lyrica CR) — Class: α2δ calcium-channel modulator. Indication: DPN and postherpetic neuralgia (PHN). Dose/time: start 150 mg/day in divided doses; titrate to 300–600 mg/day (per label/formulation). Purpose: decrease neuropathic pain and sleep disturbance. Mechanism: reduces presynaptic calcium influx and neurotransmitter release. Adverse effects: dizziness, somnolence, edema, weight gain. Label source. FDA Access Data+2FDA Access Data+2

3. Gabapentin (Neurontin/Gralise) — Class: α2δ modulator. Indication: PHN (gabapentin ER also for PHN). Dose/time: titrate to 1,800–3,600 mg/day (IR) per label specifics. Purpose: reduce neuropathic pain. Mechanism: similar to pregabalin. Adverse effects: dizziness, somnolence; dose adjust in renal impairment. Label source. FDA Access Data+1

4. Tapentadol ER (Nucynta ER) — Class: μ-opioid agonist + norepinephrine reuptake inhibition. Indication: DPN neuropathic pain requiring daily opioid therapy. Dose/time: individualized; ER tablet q12h with careful titration. Purpose: severe neuropathic pain not controlled by non-opioids. Mechanism: combines opioid analgesia with noradrenergic modulation. Warnings: addiction, respiratory depression, constipation, sedation. Label source. FDA Access Data+2FDA Access Data+2

5. Capsaicin 8% patch (Qutenza) — Class: TRPV1 agonist topical. Indication: neuropathic pain associated with DPN of the feet; PHN. Dose/time: in-clinic application to feet for 30 min; may repeat ≥every 3 months. Purpose: reduce localized neuropathic foot pain. Mechanism: defunctionalizes nociceptor terminals. Adverse effects: application-site pain/erythema; transient BP rise. FDA documents. FDA Access Data+2FDA Access Data+2

6. Lidocaine 5% patch (Lidoderm) / ZTLido 1.8% — Class: topical local anesthetic. Indication: PHN pain. Dose/time: up to 12 h/day on intact skin. Purpose: focal neuropathic pain relief (off-label extrapolation to focal CMT pain may be considered by clinicians). Mechanism: sodium-channel blockade in cutaneous nerves. Adverse effects: local skin reactions. Label source. FDA Access Data+2FDA Access Data+2

7. Tramadol (Ultram) — Class: μ-opioid agonist/monoaminergic. Indication: moderate-to-moderately severe pain. Use case: short courses when other options fail. Key warnings: addiction, seizure risk, serotonin syndrome with SSRIs/SNRIs, MAOI contraindication. Label source. FDA Access Data+1

8. NSAIDs (e.g., ibuprofen/naproxen, Rx strengths) — Class: COX inhibitors. Indication: musculoskeletal pain (joint/soft-tissue), helpful for overuse pain in CMT (not neuropathic pain). Mechanism: prostaglandin inhibition. Labels exist for Rx products; clinicians weigh GI/renal/CV risks. (Representative label references available on request.) nhs.uk

9. Duloxetine (chronic musculoskeletal pain label) — For mixed pain phenotypes (e.g., back/osteoarthritis), which can coexist in CMT. Same dosing cautions as above. FDA Access Data

10. HORIZANT (gabapentin enacarbil ER) — Indications: PHN and RLS; ER formulation may aid adherence; dosing per label. As above, used symptomatically. FDA Access Data

(If you want a full set of 20 with label quotes for each—e.g., adding TCAs with safety notes, SNRIs variants, additional topical anesthetics, careful use of opioid-sparing combinations—say so and I’ll expand with FDA citations throughout.)

---

Dietary molecular supplements

There are no supplements proven to treat CMT2-DGAT2. Some nutrients are studied in neuropathy/metabolic contexts and may support general nerve health when deficiencies exist; dosing must be individualized to avoid harm.

1. Alpha-lipoic acid — antioxidant studied in DPN; may reduce oxidative stress; monitor for hypoglycemia in diabetics.

2. Acetyl-L-carnitine — mitochondrial cofactor; small trials in neuropathic pain show mixed results.

3. Omega-3 fatty acids (EPA/DHA) — anti-inflammatory; potential membrane benefits; supports cardiovascular risk reduction.

4. Vitamin D — correct deficiency to support muscle function and fall reduction.

5. Vitamin B12 (methylcobalamin if deficient) — essential for myelination; treat deficiency-related neuropathy.

6. Folate (if deficient) — supports one-carbon metabolism; avoid masking B12 deficiency.

7. Thiamine (B1) — deficiency causes neuropathy; consider in at-risk diets.

8. Magnesium — muscle cramp support (limited evidence); avoid excess with renal disease.

9. Coenzyme Q10 — mitochondrial support; evidence in neuropathy is limited.

10. Curcumin — anti-inflammatory/antioxidant; bioavailability varies; interacts with anticoagulants.

(For each item I can produce a 150-word description with mechanisms and dosing ranges, with primary-source citations, on request.)

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity boosters,” regenerative medicines, or stem-cell drugs for any CMT subtype, including CMT2-DGAT2. Recent progress includes orphan-drug designations and early-phase gene/stem-cell trials in other CMT types, but these are investigational, not approved therapies. Examples: NMD670 (skeletal-muscle-targeted) received FDA Orphan Drug Designation, and EN001 (stem-cell therapy) also received ODD; gene-therapy programs for selected subtypes are in preclinical/early trials. None are FDA-approved for routine care. NMD Pharma+3U.S. Food and Drug Administration+3NMD Pharma+3

---

Surgeries (procedures & why they’re done)

1. Cavovarus foot reconstruction — soft-tissue balancing (e.g., plantar fascia release, peroneus longus–to–brevis transfer) plus bony osteotomies (e.g., calcaneal osteotomy) to achieve a plantigrade foot for improved gait and brace fit. PubMed+1

2. Tendon transfers for foot drop — to restore active dorsiflexion and reduce tripping. PubMed

3. Toe corrections (claw toe procedures) — relieve shoe conflict and pain, improve push-off mechanics. PMC

4. Ankle stabilization — ligament reconstructions for recurrent sprains/laxity that impair gait. Charcot-Marie-Tooth Disease

5. Arthrodesis (salvage) — in severe, rigid deformity not correctable with joint-sparing surgery to provide pain-free plantigrade alignment. PubMed

---

Prevention & self-care tips

1. Daily foot checks and skin care to catch blisters/calluses early. nhs.uk

2. Supportive shoes/orthoses to limit falls and overuse injuries. The Foundation for Peripheral Neuropathy

3. Keep moving with low-impact exercise to preserve strength/endurance. MDPI

4. Maintain healthy weight to reduce ankle/knee load. Frontiers

5. Avoid neurotoxic drugs when alternatives exist (discuss with your clinician). NCBI

6. Address pain early with non-drug strategies; add meds if needed. NCBI

7. Optimize sleep (pain control, sleep hygiene) to reduce fatigue and falls. NCBI

8. Home safety (lighting, handrails, remove trip hazards). NCBI

9. Regular physiotherapy reviews to update braces and exercises as disease evolves. cmtausa.org

10. Family counseling/testing because inheritance is autosomal dominant. Orpha

---

When to see a doctor

• You notice new foot drop, repeated falls, or rapidly worsening gait—you may need orthoses or surgical evaluation. PubMed

• You develop ulcers, infections, or severe foot pain/deformity—early orthopedic/podiatry care prevents long-term disability. PMC

• Pain becomes persistent or severe despite home measures—consider labeled neuropathic-pain treatments. NCBI

• Hand function declines (grip, fine motor tasks)—occupational therapy can help with splints and adaptations. cmtausa.org

• Family planning questions—a genetics consult can outline risks and testing options. Orpha

---

What to eat & what to avoid

Eat more: balanced meals emphasizing lean protein, vegetables, whole grains, and omega-3-rich fish; adequate B-vitamins and vitamin D if deficient. A heart-healthy, anti-inflammatory pattern supports weight control and metabolic health, which are kind to weak ankles and may favor nerve lipid balance. Hydrate well to aid training and recovery. Frontiers

Avoid/limit: excess calories that drive weight gain, heavy alcohol (neurotoxicity), very high-sugar diets that worsen metabolic stress, and deficiency states (B12, D). If you have diabetes or prediabetes, target guideline-based glycemic control to reduce neuropathic symptom burden. Frontiers

---

FAQs

1) Is there a cure?
Not yet. Treatment is symptom-focused (rehab, orthoses, surgery for deformity, pain control). Multiple investigational programs are in early stages. NCBI+2PMC+2

2) How rare is CMT2-DGAT2?
Extremely rare (single families reported); CMT2 overall is uncommon but far more prevalent. PubMed+1

3) How is it inherited?
Autosomal dominant: an affected parent has a 50% chance of passing it to a child. Orpha

4) What age does it start?
Often childhood to early adulthood with slow progression. Orpha

5) Which nerves are affected?
Longest motor and sensory axons first—feet/legs, then hands. Muscular Dystrophy Association

6) What tests confirm it?
Nerve conduction studies show axonal neuropathy; genetic testing for DGAT2 confirms. PubMed

7) Are there disease-modifying drugs?
None approved; pain drugs are used based on FDA labels for DPN/PHN or general pain. U.S. Food and Drug Administration

8) Do braces help?
Yes—AFOs and custom insoles improve stability and reduce falls; algorithms guide selection. The Foundation for Peripheral Neuropathy

9) When is surgery considered?
For cavovarus or rigid deformity impairing function or brace fit. Aim is a plantigrade foot. PubMed

10) Can exercise worsen nerves?
Appropriately graded, low-impact exercise is beneficial; overuse of weak ankles should be avoided. MDPI

11) Are supplements necessary?
Only to correct deficiencies or as clinician-advised adjuncts; none cure CMT. NCBI

12) Any role for stem cells now?
Not in routine care; some orphan-designated and preclinical programs exist but are experimental. NMD Pharma+1

13) What about diet?
Focus on weight control and metabolic health to ease joint load and possibly help nerve lipid balance. Frontiers

14) Is tremor part of it?
Tremor has been reported in DGAT2-CMT families; task adaptation helps. PubMed

15) Where can I learn more or find care?
CMT clinics and associations publish therapy guides and surgery consensus pieces helpful to patients and clinicians. cmtausa.org+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 01, 2025.